Subretinal hemorrhage

Glenn C Yiu, Tamer H. Mahmoud

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Large submacular hemorrhage (SMH) is a devastating complication of neovascular age-related macular degeneration (AMD) that cannot be effectively managed with anti-vascular endothelial growth factor injections alone. While SMH is not common, AMD patients with existing coagulopathies or taking anticoagulant medications are particularly susceptible. Today, various techniques are available for the management of SMH, including pneumatic displacement with or without intravitreal tissue plasminogen activator (tPA), pars plana vitrectomy with subretinal tPA and gas tamponade, and submacular surgery with vitrectomy and retinotomy for clot extraction. While no consensus exists, the preferred technique is often determined by the extent or duration of the hemorrhage and surgeon preference. This chapter reviews treatment options for managing SMH, as well as the current evidence for supporting their use.

Original languageEnglish (US)
Pages (from-to)213-222
Number of pages10
JournalDevelopments in Ophthalmology
Volume54
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Hemorrhage
Vitrectomy
Macular Degeneration
Tissue Plasminogen Activator
Temazepam
Anticoagulants
Vascular Endothelial Growth Factor A
Gases
Injections
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Subretinal hemorrhage. / Yiu, Glenn C; Mahmoud, Tamer H.

In: Developments in Ophthalmology, Vol. 54, 2014, p. 213-222.

Research output: Contribution to journalArticle

Yiu, Glenn C ; Mahmoud, Tamer H. / Subretinal hemorrhage. In: Developments in Ophthalmology. 2014 ; Vol. 54. pp. 213-222.
@article{c0a03b28e91b4df6b047f77decb08fa4,
title = "Subretinal hemorrhage",
abstract = "Large submacular hemorrhage (SMH) is a devastating complication of neovascular age-related macular degeneration (AMD) that cannot be effectively managed with anti-vascular endothelial growth factor injections alone. While SMH is not common, AMD patients with existing coagulopathies or taking anticoagulant medications are particularly susceptible. Today, various techniques are available for the management of SMH, including pneumatic displacement with or without intravitreal tissue plasminogen activator (tPA), pars plana vitrectomy with subretinal tPA and gas tamponade, and submacular surgery with vitrectomy and retinotomy for clot extraction. While no consensus exists, the preferred technique is often determined by the extent or duration of the hemorrhage and surgeon preference. This chapter reviews treatment options for managing SMH, as well as the current evidence for supporting their use.",
author = "Yiu, {Glenn C} and Mahmoud, {Tamer H.}",
year = "2014",
doi = "10.1159/000360469",
language = "English (US)",
volume = "54",
pages = "213--222",
journal = "Developments in Ophthalmology",
issn = "0250-3751",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Subretinal hemorrhage

AU - Yiu, Glenn C

AU - Mahmoud, Tamer H.

PY - 2014

Y1 - 2014

N2 - Large submacular hemorrhage (SMH) is a devastating complication of neovascular age-related macular degeneration (AMD) that cannot be effectively managed with anti-vascular endothelial growth factor injections alone. While SMH is not common, AMD patients with existing coagulopathies or taking anticoagulant medications are particularly susceptible. Today, various techniques are available for the management of SMH, including pneumatic displacement with or without intravitreal tissue plasminogen activator (tPA), pars plana vitrectomy with subretinal tPA and gas tamponade, and submacular surgery with vitrectomy and retinotomy for clot extraction. While no consensus exists, the preferred technique is often determined by the extent or duration of the hemorrhage and surgeon preference. This chapter reviews treatment options for managing SMH, as well as the current evidence for supporting their use.

AB - Large submacular hemorrhage (SMH) is a devastating complication of neovascular age-related macular degeneration (AMD) that cannot be effectively managed with anti-vascular endothelial growth factor injections alone. While SMH is not common, AMD patients with existing coagulopathies or taking anticoagulant medications are particularly susceptible. Today, various techniques are available for the management of SMH, including pneumatic displacement with or without intravitreal tissue plasminogen activator (tPA), pars plana vitrectomy with subretinal tPA and gas tamponade, and submacular surgery with vitrectomy and retinotomy for clot extraction. While no consensus exists, the preferred technique is often determined by the extent or duration of the hemorrhage and surgeon preference. This chapter reviews treatment options for managing SMH, as well as the current evidence for supporting their use.

UR - http://www.scopus.com/inward/record.url?scp=84929502567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929502567&partnerID=8YFLogxK

U2 - 10.1159/000360469

DO - 10.1159/000360469

M3 - Article

C2 - 25196772

AN - SCOPUS:84929502567

VL - 54

SP - 213

EP - 222

JO - Developments in Ophthalmology

JF - Developments in Ophthalmology

SN - 0250-3751

ER -